Drugs / ABBV-553
last change Aug 2017 re-read 3 minutes ago

ABBV-553

Developed for
psoriasis
Investigated by
AbbVie

Trials 1

2018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03145948 May → Aug 2017 psoriasis AbbVie Terminated No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as ABBV-553 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03145948 ↗
Route Oral “It is administered orally.” NCT03145948 ↗